We hypothesize that patients receiving either LLLT or MET would demonstrate superior improvement in terms of shoulder function, pain intensity, shoulder ROM, interleukin 6 (IL-6), depression, anxiety, and QoL compared to those receiving CTE. This evidence concerns the gene IL6 and depressive symptom measurement.